Keiji Nogami

Professor
Nara Medical University, Nara, Japan
Nara, Nara, Japan

Presentation(s):

• PB0210 - Development of modified factor VIII for effective hemophilia A gene therapy

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0218 - Establishment of inhibitor development system and analysis of inhibitor properties in novel mild/moderate hemophilia A model mice

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0910 - A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, and 1982_1983del).

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 49.5 - FVIII mutated with D519V/E665V/K1813A enhances coagulation potentials by high affinity for FIXa and stabilizing A2 domain

  Monday, June 24, 2024
  15:45 – 16:00 ICT

• OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study

  Tuesday, June 25, 2024
  09:30 – 09:45 ICT

• OC 50.4 - Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in hemophilia A with inhibitor (UNEBI Study): Multicenter open-label non-randomized trial.

  Tuesday, June 25, 2024
  10:15 – 10:30 ICT

• PB1232 - Impact of anticoagulant function by the addition of heparinoid in vitro in the plasmas from patients with hemophilia

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1111 - Usefulness of hybrid human-porcine factor VIII for emicizumab-treated patients with hemophilia A and inhibitors

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT